• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
FULC

FULC

Fulcrum Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD3.22

+0.08 (+2.55%)

Rating:C+

Company Profile

CEO

Alexander C. Sapir

IPO Date

2019-07-18

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.10

Prev. Close

$3.14

Day Low

$3.10

Day High

$3.27

52W Low

$2.83

52W High

$15.74

Market Cap

$0.17B

Volume

5.59M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

44.2%

Avg Negative

2.5%

Avg Neutral

53.3%

News Feed

Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function

GlobeNewsWire·6/24/2021·↑ positive

Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation

Benzinga·5/12/2021·↑ positive

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

GlobeNewsWire·5/12/2021·↑ positive

Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/8/2021·↓ negative

Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

GlobeNewsWire·5/7/2021·↑ positive

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

GlobeNewsWire·5/6/2021·↑ positive

Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference

GlobeNewsWire·4/9/2021·↑ positive

Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D.

GlobeNewsWire·3/24/2021·↑ positive

FULC Stock Price Increases Over 40% Pre-Market: Why It Happened

Pulse2·3/23/2021·↑ positive

Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

GlobeNewsWire·3/18/2021·↑ positive